CERO Therapeutics Holdings, Inc. announced key appointments to its management team on October 2, 2024, to support Interim CEO Chris Ehrlich. Andrew Albert 'Al' Kucharchuk has been named Chief Financial Officer, bringing extensive experience in C-suite positions at publicly traded life sciences companies.
Kristen Pierce, Ph.D., was appointed Chief Development Officer, with over 20 years of oncology experience leading nonclinical and early clinical stage projects. Her background includes roles at Pionyr Therapeutics and Pfizer Therapeutics, where she led development of antibody and small molecules in oncology.
These appointments are intended to strengthen the company's leadership as it aims to advance its lead compound, CER-1236, into clinical development. The new management team is tasked with driving CERO Therapeutics forward into the clinic and achieving its strategic goals.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.